Retatrutide: Single-molecule triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously
In most patients, the effectiveness of hormone therapy starts working in 1 or 2 weeks after receiving treatment
Awaiting the final research studies and FDA approval will bring in relevant guidance on dosing and also assure that sourcing is vetted, regulated, safe, and reliableand not from the unregulated gray market
Native rhIGF-1 (mecasermin, brand name Increlex) is FDA-approved only for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency or with GH gene deletion who have developed neutralizing antibodies to GH
Ovulation may not happen every month in teenagers, which is why cycles can vary significantly
A realistic plan may include balanced meals, regular physical activity, hydration, sleep support, and routine check-ins with a healthcare provider